Masaru Miura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8767139/publications.pdf

Version: 2024-02-01

10	1,011	7	10
papers	citations	h-index	g-index
10	10	10	885
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet, The, 2012, 379, 1613-1620.	13.7	560
2	JCS/JSCS 2020 Guideline on Diagnosis and Management of Cardiovascular Sequelae in Kawasaki Disease. Circulation Journal, 2020, 84, 1348-1407.	1.6	154
3	A New Z Score Curve of the Coronary Arterial Internal Diameter Using the Lambda-Mu-Sigma Method inÂaÂPediatric Population. Journal of the American Society of Echocardiography, 2016, 29, 794-801.e29.	2.8	150
4	Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study. The Lancet Child and Adolescent Health, 2018, 2, 855-862.	5.6	63
5	Nationwide Survey of Patients With Giant Coronary Aneurysm Secondary to Kawasaki Disease 1999–2010 in Japan. Circulation Journal, 2018, 82, 239-246.	1.6	39
6	Risk Factors of Coronary Artery Abnormalities and Resistance to Intravenous Immunoglobulin Plus Corticosteroid Therapy in Severe Kawasaki Disease. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007191.	2.2	21
7	Risk Factors of Coronary Artery Aneurysms in Kawasaki Disease with a Low Risk of Intravenous Immunoglobulin Resistance: An Analysis of PostÂRAISE. Journal of Pediatrics, 2022, 240, 158-163.e4.	1.8	10
8	Evaluation of a Kawasaki Disease Risk Model for Predicting Coronary Artery Aneurysms in a Japanese Population: An Analysis of Post RAISE. Journal of Pediatrics, 2021, 237, 96-101.e3.	1.8	5
9	Follow-Up Duration of Echocardiography in Patients with Kawasaki Disease with No Initial Coronary Aneurysms. Journal of Pediatrics, 2022, 244, 133-138.e1.	1.8	5
10	Cardiovascular toxicity of regorafenib for heavilyâ€treated osteosarcoma. Pediatrics International, 2021, 63, 857-859.	0.5	4